11:56 AM EST, 11/16/2026 (MT Newswires) -- The European stock markets closed mostly lower in Monday trading as investors continued to parse earnings reports, and ahead of Thursday's planned summit of US President Donald Trump, Russian President Vladimir Putin, and Chinese President Xi Jinping.
The Stoxx Europe was off 0.2%, Germany's DAX dropped 0.5%, the FTSE 100 was off 0.1%, France's CAC declined 0.2%, while the Swiss Market Index rose 0.7%.
In corporate news, Novo Nordisk's investigational treatment CagriSema has been linked to a 25% mean weight loss among early responders in two analyses of a phase 3 study, the company said.
The trial was of a fixed-dose combination of 2.4mg of the long-acting amylin analog cagrilintide and 2.4mg of the GLP-1 receptor agonist semaglutide in overweight or obese adults, the company said.
Lower doses of the treatment at 1.7mg and 1mg showed around a 21% average weight loss in a separate clinical study, the company said. Adverse events in both studies were mostly "mild to moderate" in severity, the company said.
A decision on Novo's US Food and Drug Administration new drug application for the higher-dose version is expected in Q4, the company said.
Shares of the Danish pharmaceutical company rose 2.4% in Copenhagen.
Novartis signed a collaboration and license agreement with OBI Pharma for the development of antibody-drug conjugates, or ADCs, with novel payloads using OBI's ADC platform technologies, according to a Friday statement.
OBI Pharma said it will receive an upfront $30 million payment for the agreement and will be eligible for over $2 billion in milestone payments, plus royalties on sales of any future products.
The deal gives Novartis exclusive worldwide rights to certain OBI patents and use ADC platform technologies for selected, undisclosed Novartis payload classes, with an option to expand the agreement for additional novel payload classes, OBI Pharma added.
OBI Pharma also said it will evaluate novel linker approaches with Novartis' selected payloads as part of the collaboration.
Shares of the Swiss pharmaceutical company gained 1.3% in Zurich.
Banco Santander and Goldman Sachs are selling significant risk transfers for large corporate loan portfolios as deal activity in the space hits records, Bloomberg News reported Monday, citing people familiar with the matter.
Santander is working on a transaction tied to roughly $8 billion of lending across the US and other regions, while Goldman Sachs is structuring a deal through its Absolute program, the news outlet quoted the people as saying.
UniCredit is in discussions with investors over a separate transaction involving 1.5 billion euros ($1.7 billion) of Italian consumer loans, Bloomberg reported.
Banco Santander, Goldman Sachs and UniCredit did not immediately respond to MT Newswires' request for comment.
Shares of Banco Santander declined 0.4% in Madrid.
Nokia and technology partners Nscale, Skeleton, Telia and Verda have formed the AI Gigafactory Northern consortium to develop a federated AI infrastructure across the Nordic and Baltic regions, the companies said Monday.
The consortium plans to bid under the European High-Performance Computing Joint Undertaking's AI Gigafactory program and build a network of sites combining large-scale AI computing, sovereign cloud services, high-capacity connectivity and decarbonized energy, they said.
The planned infrastructure will connect facilities in Finland, Estonia, Latvia, and a future site in Sweden, the companies said.
Shares of the Finnish telecommunications company dropped 1.2% in Helsinki.
GSK's majority-owned ViiV Healthcare said Monday that a committee of the European Medicines Agency has recommended approval to expand the use of its HIV drugs Tivicay and Dovato in younger age groups, including eligible newborns.
The Committee for Medicinal Products for Human Use recommended extending the use of Tivicay's dispersible tablets, in combination with other antiretroviral medicines, to treat HIV in adults, adolescents, children and newborns weighing at least 2 kilograms, ViiV said.
The committee also recommended approval of Dovato's new dispersible tablet formulation for treating HIV-1 infection in children aged at least 3 months and weighing at least 6 kg but less than 25 kg. Additionally, it recommended expanding the use of Dovato's existing film-coated tablets to children weighing at least 20 kg, the company said.
The European Commission's decision is expected in Q1 of 2027, the company said.
Shares of GSK increased 0.8% in London.
http://www.mtnewswires.com
Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.